Your browser doesn't support javascript.
loading
Muscle wasting: emerging pathways and potential drug targets.
Domaniku, Aylin; Bilgic, Sevval Nur; Kir, Serkan.
Afiliação
  • Domaniku A; Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkey.
  • Bilgic SN; Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkey.
  • Kir S; Department of Molecular Biology and Genetics, Koc University, Istanbul 34450, Turkey. Electronic address: skir@ku.edu.tr.
Trends Pharmacol Sci ; 44(10): 705-718, 2023 10.
Article em En | MEDLINE | ID: mdl-37596181
Muscle wasting is a serious comorbidity associated with many disorders, including cancer, kidney disease, heart failure, and aging. Progressive loss of skeletal muscle mass negatively influences prognosis and survival, and is often accompanied by frailty and poor quality of life. Clinical trials testing therapeutics against muscle wasting have yielded limited success. Some therapies improved muscle mass in patients without appreciable differences in physical performance. This review article discusses emerging pathways that regulate muscle atrophy, including oncostatin M (OSM) and ectodysplasin A2 (EDA2) receptor (EDA2R) signaling, outcomes of recent clinical trials, and potential drug targets for future therapies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Atrofia Muscular Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Atrofia Muscular Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article